Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1592]
News [3736]
Articles [310]
Editorials [10]
Conferences [81]
elearning [26]
Palbociclib combination in advanced breast cancer: Again only disadvantages
Palbociclib combination in advanced breast cancer: Again only disadvantages
Clues found regarding tumour suppressor gene’s breast cancer activity
Clues found regarding tumour suppressor gene’s breast cancer activity
SABCS 2022: Breast-conserving therapy may be a treatment option for some patients with multiple breast lesions
SABCS 2022: Breast-conserving therapy may be a treatment option for some patients with multiple breast lesions
SABCS 2022: Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not experience worse short-term recurrence rates
SABCS 2022: Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not experience worse...
SABCS 2022: Camizestrant may be superior to fulvestrant in hormone receptor-positive, HER2-negative breast cancer
SABCS 2022: Camizestrant may be superior to fulvestrant in hormone receptor-positive, HER2-negative breast cancer
SABCS 2022: Genetic profiling may identify patients with breast cancer who can safely omit radiation therapy after breast-conserving surgery
SABCS 2022: Genetic profiling may identify patients with breast cancer who can safely omit radiation therapy after...
SABCS 2022: The TAILORx trial in over 10,000 women with early breast cancer reaches 12 years of recurrence and survival outcomes
SABCS 2022: The TAILORx trial in over 10,000 women with early breast cancer reaches 12 years of recurrence and...
SABCS 2022: Treatment decision guided by CTC count may improve long-term outcomes for mBC
SABCS 2022: Treatment decision guided by CTC count may improve long-term outcomes for mBC
SABCS 2022: Adding capivasertib to fulvestrant improves progression-free survival in patients with advanced hormone receptor-positive breast cancer
SABCS 2022: Adding capivasertib to fulvestrant improves progression-free survival in patients with advanced...
SABCS 2022: Neoadjuvant trastuzumab deruxtecan shows clinical activity in patients with HER2-low breast cancer
SABCS 2022: Neoadjuvant trastuzumab deruxtecan shows clinical activity in patients with HER2-low breast cancer

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation